Management of hepatitis B in liver transplant patients

Journal of Clinical Gastroenterology

Volumn 39, Issue 1, 2005, Pages 58-63

  Mohanty, Smruti R ^a   Cotler, Scott J ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

HBIG and nucleoside analogs; HBV; Liver; Post transplantation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CIRCULAR DNA; CLEVUDINE; CORTICOSTEROID; DNA POLYMERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; LEUCINE; MERCURY; METHIONINE; NARCOTIC AGENT; NUCLEOSIDE DERIVATIVE; PHOSPHORYL LIPID A; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; VIRUS DNA;

ALLOGRAFT; ANTIBODY TITER; BACKACHE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FLUSHING; HEADACHE; HEALTH CARE COST; HEPATITIS B; HUMAN; HYBRIDIZATION; IMMUNOPROPHYLAXIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RASH; REVIEW; SEROCONVERSION; SURVIVAL; THORAX PAIN; VACCINATION; VIRION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS;

EID: 11144327181     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Seaberg EC, Belle SH, Beringer KC, et al. Liver transplantation in the United States from 1987-1998: updated results from Pitt-UNOS liver registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998. Los Angeles: UCLA Tissue Typing Laboratory, 1999:17-37.
2. European Liver Transplant R. Registry for the European liver transplant association, data analysis, 05/1968-12/2000, http:/www.eltr.org
3. Lo CM, Fan ST, Liu CL, et al. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation. 2003;76(suppl):41-44.
4. Todo S, Demetris AJ, Van Thiel D, et al. Orthotpic liver tansplantation for patients with hepatitis B virus related liver disease. Hepatology. 1991;13:619-626.
5. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus re-infection after orthotopic liver transplantation: serological and clinical implications. J Hepatol. 1992;14:104-111.
6. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842-1847.
7. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol. 1992;14:104-111.
8. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24:1327-1333.
9. Muller R, Gubematis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers: prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol. 1991;13:90-96.
10. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet. 1991;337:813-815.
11. Rinoldi P, Belli L, Rondinara G, et al. Recurrent HBV/HDV infections under different immunoprophylaxis protocols. Transplant Proc. 1993;25:2675-2676.
12. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35:1528-1535.
13. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908-916.
14. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-68.
15. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol. 2003;39:466-474.
16. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993;104:1116-1121.
17. Tchervenkov J, Tector A, Barkun J, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis immune globulin posttransplant. Ann Surg. 1997;226:356-365.
18. Marcellin P, Samuel D, Areias J, et al. Pretransplant interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related endstage liver disease. Hepatology. 1994;19:6-12.
19. Dienstag JL, Perrilo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-1661.
20. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
21. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut. 2000;46:562-568.
22. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-180.
23. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527-1532.
24. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B mutations in the polymerase region. Hepatology. 2001;33:751-757.
25. Liaw Y-F. Results of lamivudine in Asian Trials. Proceedings of EASL International Consensus Conference on Hepatitis B, 2002.
26. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
27. Xiong S, Yang H, Westland CE, et al. Resistance survilance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with Adefovir dipivoxil(ADV) [Abstract]. J Hepatol. 2003;(suppl 2):182A.
28. Peters MG, Hann HW, Martin P, et al. Adefovir Dipivoxil alone on in combination with lamivudine in patients with lamivudine-resistance chronic hepatitis B. Gastroenterology. 2004;126:91-101.
29. Villeneuve JP, Condrey LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207-210.
30. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol. 2000;33:301-307.
31. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000;33:308-312.
32. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology. 2001;33:424-432.
33. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411-416.
34. Fontana R, Keeffe E, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433-439.
35. Fontana RJ, Hann H-WL, Perrillo RP, et al. Determinants of early mortality in patients in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719-727.
36. Rosenau J, Bahr M, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001;34:895-902.
37. Shouval D, Samuel D. Hepatitis immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32:1189-1195.
38. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg. 1998;227:841-850.
39. Waters JA, Brown SE, Steward WN. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of protective antibody response. Virus Res. 1992;33:1-12.
40. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61:1358-1364.
41. Prozer-Knolle U, Neumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998;27:254-263.
42. Trautwein C, Schrem H, Tillman HL, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology. 1996;24:482-488.
43. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutations in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998;27:213-222.
44. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 1996;348:1212-1215.
45. Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation. 2000;70:809-815.
46. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B titre predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation. J Hepatol. 1999;30:715-721.
47. Chan HLY, Chui AKK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol. 2002;68:182-187.
48. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34:903-910.
49. Yao FY, Osofio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg. 1999;5:491-496.
50. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globin. Liver Transpl Surg. 1999;5:520-525.
51. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6:429-433.
52. Lee PH, Hu RH, Tsai MK, et al. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous anti-hepatitis B immunoglobulin and lamivudine. Transplant Proc. 2000;32:2245-2247.
53. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg. 1999;6:512-519.
54. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2001;6:741-748.
55. Anselmo D, Ghobrial R, Jung LL, et al. New era of liver transplantation of hepatitis B: a 17-year single-center experience. Ann Surg. 2002;235:611-620.
56. Gane EJ, McCaughan G, Crawford D, et al. Combination lamivudine plus low dose intramuscular hepatitis B immunoglobulin prevents recurrent hepatitis B and may eradicate residual graft infection. Hepatology. 2002;36:221A.
57. Locamini SA, Civitico GM, Newbold JE. Hepatitis B: New approaches for antiviral chemotherapy. Antivir Chem Chemother. 1996;7:1-12.
58. Dodson F, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000;6:434-439.
59. Terrault NA, Wright TL, Roberts JP, et al. Combined short-term hepatitis B immunoglobulin and long-term lamivudine versus hepatitis B immunoglobulin monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology. 1998;28:389A.
60. Vierling JM, Teperman LW, Lake JR, et al. Case studies of the hepatitis B patient: a panel discussion. Semin Liver Dis. 2000;20(suppl):29-35.
61. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination: a new strategy in the prophylaxis hepatitis B virus recurrence after liver transplantation. Hepatology. 2000;31:496-501.
62. Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation. Hepatology. 2002;36:257-258.
63. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35:176-181.
64. Bienzle U, Gunther M, Neuhaus R, et al. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl. 2002;8:562-564.
65. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
66. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir Dipivoxil therapy for lamivudine-resistant hepatitis B pre- and post-liver transplantation patients. Hepatology. 2003;38:1419-1427.
67. Perrillo R, Hann HW, Mutimer D, et al. Adefovir Divoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant Hepatitis B virus. Gastroenterology. 2004;126:81-90.
68. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology. 1999;29:1581-1586.
69. Castells L, Vargas V, Rodriguez F, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl. 2002;8:892-900.
70. Tillman HL, Bock CT, Bleck JS, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir Dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl. 2003;9:191-196.
71. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut. 2001;49:436-440.
72. Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut. 2001;49:860-863.
73. Beckebaum S, Malago M, Olaf D, et al. The efficacy of combined lamivudine and adefovir dipivoxil treatment for sever HBV graft infection after living donor liver transplantation. Clin Transpl. 2004;17:554-559.